(Q37847179)

24 August 2017

1 reference

title

Current status of agents active against the T315I chronic myeloid leukemia phenotype (English)

1 reference

24 August 2017

main subject

chronic myeloid leukemia

0 references

1 reference

Aine Carol Burke

1

1 reference

24 August 2017

Ronan T Swords

series ordinal

2

1 reference

24 August 2017

Kevin Kelly

series ordinal

3

1 reference

24 August 2017

Francis J Giles

series ordinal

4

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

Expert Opinion on Emerging Drugs

24 August 2017

published in

1 reference

24 August 2017

volume

16

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

85-103

1 reference

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Allosteric inhibitors of Bcr-abl-dependent cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Aurora kinases in spindle assembly and chromosome segregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Novel dual Src/Abl inhibitors for hematologic and solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase includ

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Inhibitors of ABL and the ABL-T315I mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Adaphostin cytoxicity in glioblastoma cells is ROS-dependent and is accompanied by upregulation of heme oxygenase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

BIRB-796 is not an effective ABL(T315I) inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR , Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Ras as a therapeutic target in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Identification of a novel inhibitor of mitogen-activated protein kinase kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Induction of Apoptosis in BCR/ABL+ Cells By Histone Deacetylase Inhibitors Involves Reciprocal Effects on the RAF/MEK/ERK and JNK Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Modulating autophagy for therapeutic benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Clinical studies of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

BCR/ABL regulation of PI-3 kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Degrasyn activates proteasomal-dependent degradation of c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Resveratrol induces apoptosis in K562 (chronic myelogenous leukemia) cells by targeting a key survival protein, heat shock protein 70.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Molecular mechanisms of action of antisense drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Antisense properties of peptide nucleic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.531698

10.1517/14728214.2011.531698

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference